C. Abeni

Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.

A. Farolfi, V. Carbone, T. Di Palma, 2024, Gynecologic oncology.

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Gadducci, A. Lissoni, S. Cosio, 2024, The Lancet. Oncology.